The Bim deletion polymorphism clinical profile and its relation with tyrosine kinase inhibitor resistance in Chinese patients with non–small cell lung cancer

Publisher： John Wiley & Sons Inc

E-ISSN： 1097-0142|120|15|2299-2307

ISSN： 0008-543x

Source： CANCER, Vol.120, Iss.15, 2014-08, pp. : 2299-2307

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Rebiopsy of non–small cell lung cancer patients with acquired resistance to epidermal growth factor receptor‐tyrosine kinase inhibitor

By  

CANCER, Vol. 119, Iss. 24, 2013-12 ,pp. : 4325-4332

John Wiley & Sons Inc

Access to resources Recommend Favorite

Challenges in the Management of EGFR-Mutated Non-Small Cell Lung Cancer Patients with Acquired Resistance to Tyrosine Kinase Inhibitors

By  

Oncology, Vol. 87, Iss. 2, 2014-07 ,pp. : 83-94

Karger

Access to resources Recommend Favorite

Clinical Predictors of Response to EGFR Tyrosine Kinase Inhibitors in Patients with EGFR-Mutant Non-Small Cell Lung Cancer

By  

Oncology, Vol. 86, Iss. 2, 2014-01 ,pp. : 86-93

Karger

Access to resources Recommend Favorite

Volumetric tumor growth in advanced non‐small cell lung cancer patients with EGFR mutations during EGFR‐tyrosine kinase inhibitor therapy

By  

CANCER, Vol. 119, Iss. 21, 2013-11 ,pp. : 3761-3768

John Wiley & Sons Inc

Access to resources Recommend Favorite

EML4-ALK Rearrangement and Its Clinical Significance in Chinese Patients with Advanced Non-Small Cell Lung Cancer

By  

Oncology, Vol. 83, Iss. 5, 2012-09 ,pp. : 248-256

Karger

Access to resources Recommend Favorite